anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Although there are several psychological theories on bipolar disorders (BD), the empirical evidence on these theories through experimental studies is still limited. The current study systematically reviews experimental methods used in studies on the main theories of BD: Reward Hypersensitivity Theory (RST) or Behavioral Activation System (BAS), Integrative Cognitive Model (ICM), Positive Emotion Persistence (PEP), Manic Defense theory (MD), and Mental Imagery (MI). The primary aim is to provide an overview of the used methods and to identify limitations and suggest areas of improvement.
METHODS: A systematic search of six databases until October 2023 was conducted. Study selection involved two independent reviewers extracting data on experimental study design and methodology.
RESULTS: A total of 84 experimental studies were reviewed. BAS and RST were the most frequently studied theories. The majority of these experimental studies focus on mechanisms of reward sensitivity. Other important elements of the reviewed theories, such as goal setting and-attainment, situation selection (avoidance or approach), activation, affective/emotional reactivity, and regulatory strategies, are understudied. Self-report and neuropsychological tasks are most often used, while mood induction and physiological measures are rarely used.
CONCLUSION: There is a need for more consensus on the operationalization of psychological theories of mania. Standardization of test batteries could improve comparability among studies and foster a more systematic approach to experimental research. Research on affective (activated) states is still underrepresented in comparison with studies on trait vulnerabilities.
In this experimental study we aimed to investigate the biochemical and histopathological effects of concomitantly administered taxifolin on tramadol-induced liver damage in rats. The rats were divided into three groups; control group (CG), tramadol alone (TRG), and taxifolin + tramadol given (TTRG) groups. Malondialdehyde (MDA), total glutathione (tGSH), total oxidant status (TOS), total antioxidant status (TAS), nuclear factor-kappa beta (NF-kB), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) levels were measured in liver tissues. Liver tissues were also examined histopathologically. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were determined in blood samples. In tissue analyses, determinants of oxidative stress and inflammation, all were significantly higher in the TRG group compared with the control and TTRG groups. In the TTRG group, all oxidative stress and inflammation markers were significantly lower than in the TRG group. In addition, there was not any significant difference between the control and TTRG groups regarding the TOS and TAS status. Serum liver enzymes were also significantly higher in the TRG group than in the other two groups. In histopathological examinations, the control group had a normal histological appearance. Degenerative-necrotic hepatocytes and hemorrhage, which were seen at a severe level in the TRG group, were found to be moderate in the treated TTRG group. In addition, mononuclear cell infiltrations were found to be severe in the TRG group and mild in the treated TTRG group. Finally it was concluded that Taxifolin alleviated the toxic effects of tramadol on the liver including the histopathological and biochemical changes as well as the oxidative damage.
A lighter blanket will be worn overnight for 3 months. Blanket weight cannot be disclosed without unblinding participants.
In the RFVM, patients will be allowed to receive restricted visits according routine ICU practices, but respecting the maximum limit of 4.5 hours of visitation per day. Visitors will not be required to attend the structured meeting. The length of ICU visits will be similar to those of social visits in the FFVM.
To provide new means for enhancing functionality of a lactic acid bacterium and effectively using the bacterium.SOLUTION: A composition containing lactic acid bacterium contains Bifidobacterium lactic acid bacterium, Lactobacillus lactic acid bacterium, Lactococcus lactic acid bacterium, and Streptococcus lactic acid bacterium, and the lactic acid bacteria are a heated and sterilized body. Further, composition for immunostimulation contains Bifidobacterium lactic acid bacterium, Lactobacillus lactic acid bacterium, Lactococcus lactic acid bacterium, and Streptococcus lactic acid bacterium, and the lactic acid bacteria are a heated and sterilized body. These compositions may further include a heated and sterilized body of Enterococcus lactic acid bacterium. Further, 20 types or more of lactic acid bacteria may be included as the lactic acid bacteria. Further, lactic acid bacteria derived from enterobacteria may be included as the lactic acid bacterium. Furthermore, the composition may be in a mode of drink/food product, medicine, animal feeding stuff or the like.SELECTED DRAWING: None
PURPOSE:To provide a method for producing a coated inorganic pigment improved in water dispersibility and used for bath agents having rich hues. CONSTITUTION:50-200 pts.wt. of a water-soluble polymeric substance is dissolved in 50-300 pts.wt. of purified water under stirring at 20-80 deg.C for 0.5-3.0hr, and the produced solution is mixed with 50-150 pts.wt. of the powder of a pigment such as a white pigment, e.g. titanium oxide, zinc oxide or tale or a colored pigment yellow iron oxide, red iron oxide or ultramarine under stirring for 10-15min at the ordinary temperature. The dispersion is dried with an air- blowing constant temperature drier at 100-150 deg.C for 10-30hr, ground into 60-200 meshes with a grinder to obtain a coated inorganic pigment. The inorganic pigment is added to a bath agent in an amount of 0.1-20.0wt.%.
Despite the proven efficacy of the disease-modifying therapy (DMT) for multiple sclerosis (MS), the rates of non-adherence are frequently high. We aimed to evaluate the rate of non-adherence to the first DMT in Upper Egypt and identify different contributing factors. Out of 310 patients, ninety-seven adult patients with RRMS were recruited from three MS units located in Upper Egypt and were subjected to the following: complete clinical history, expanded disability status score (EDSS), Eight-item Morisky Medication Adherence Scale (MMAS-8), abbreviated Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9), Hamilton depression scale, Fatigue Severity Scale (FSS) and the Pittsburgh Sleep Quality Index (PSQI). According to MMAS-8 scores, 63 (64.9%) of patients were non-adherent to their first DMT. Non-adherent patients are more likely to have longer disease duration (p = 0.002), longer duration on first DMT (p = 0.030), first DMT-start date before 2019 (p = 0.040), and lower treatment satisfaction scores (p = 0.016). However, there was no significant relation with physical disability, depression, fatigue, or sleep quality. On the regression analysis model, a lower treatment satisfaction score was the only predictor of DMT non-adherence (p = 0.012). Despite expanding DMT options, non-adherence among MS patients in Upper Egypt is high. Treatment satisfaction with DMT is the only predictor of adherence among MS patients of Upper Egypt. Adherence and satisfaction with the prescribed DMT should be assessed carefully to maximize DMT benefits.
The invention discloses a medicament for treating senile dementia and a preparation method thereof. The medicament consists of active ingredients or pharmaceutically acceptable carriers. The medicament is prepared from the following active ingredients in part by weight: 1 to 15 parts of pinellia tuber, 1 to 15 parts of bamboo shavings, 1 to 15 parts of immature bitter orange, 1 to 15 parts of grassleaf sweelflag rhizome, 1 to 15 parts of thinleaf milkwort root-bark, 1 to 10 parts of ginseng, 1 to 15 parts of ligusticum wallichii and 1 to 20 parts of prepared rehmannia rhizome. The medicament is also prepared from one or more raw materials in part by weight: 1 to 15 parts of Japanese ginseng, 1 to 15 parts of tuckahoe, 1 to 15 parts of dried orange peel, 1 to 10 parts of white mustard seed, 1 to 10 parts of leech and 1 to 20 parts of prepared multiflower knotweed tuber. The medicament can be prepared into formulations such as powder, tablets, capsules, dispersible tablets, pellets, injection, oral liquid and granules. The preparation method comprises the following steps of: chopping raw materials into small pieces or crushing the raw materials into coarse powder, mixing extracts of the raw materials, which are obtained by using water or ethanol, or continuing concentrating to form dry extractum, or mixing the mixture of the extracts and the carriers. Clinical application proves that the medicament is an effective medicament for treating alzheimer's diseases and improving the memory, cognitive disorder and living abilities of patients.
The use of preimplantation genetic testing for aneuploidy (PGT-A) in the United States has been increasing steadily. Moreover, the underlying technology used for 24-chromosome analysis continues to evolve rapidly. The value of PGT-A as a routine screening test for all patients undergoing in vitro fertilization has not been demonstrated. Although some earlier single-center studies reported higher live-birth rates after PGT-A in favorable-prognosis patients, recent multicenter, randomized control trials in women with available blastocysts concluded that the overall pregnancy outcomes via frozen embryo transfer were similar between PGT-A and conventional in vitro fertilization. The value of PGT-A to lower the risk of clinical miscarriage is also unclear, although these studies have important limitations. This document replaces the document of the same name, last published in 2018.
A present invention relates to a functional complex crude drug fermented liquid which eliminates problems such as toxicity and side effects by fermenting drug materials such as Leonurus sibiricus L., Chrysanthemum zawadskii var. latilobum, Artemisia vulgaris, ginseng, and ginger which are used as crude drugs; and a method for manufacturing the same. The method comprises the steps of: preparing Leonurus sibiricus L., Chrysanthemum zawadskii var. latilobum, Artemisia vulgaris, ginseng, and ginger as raw materials; washing and drying each ingredient; and mixing the ingredients and sugar in a weight ratio of 1:1 and fermenting the mixture. The ingredient includes 15-30 wt% of Leonurus sibiricus L., 15-30 wt% of Chrysanthemum zawadskii var. latilobum, 15-30 wt% of Artemisia vulgaris, 10-15 wt% of ginseng, and 15-20 wt% of ginger. The functional complex crude drug fermented liquid and the method for manufacturing the same hardly cause toxicity and side effects, thereby being used for long-term administration with safety for the purpose of prevention. [Reference numerals] (S10) Prepare raw materials;(S20) Wash;(S30) Dry;(S40) Mix;(S50) Ferment
INTRODUCTION: Melatonin, a hormone produced by the pineal gland, regulates the sleep-wake cycle and is effective in restoring biological rhythms. Prolonged-release melatonin (PRM) is designed to mimic the natural physiological pattern of melatonin release. In circadian medicine, PRM can be used to treat sleep and circadian rhythm disorders, as well as numerous organic diseases associated with sleep disorders.
EVIDENCE ACQUISITION: This systematic review analyzed 62 studies and adhered to the PRISMA guidelines, examining the effectiveness of PRM in organic pathologies and mental disorders.
EVIDENCE SYNTHESIS: The main evidence concerns primary insomnia in subjects over the age of 55, showing significant improvements in sleep quality. In neurodevelopmental disorders, there is evidence of a positive impact on sleep quality and quality of life for patients and their caregivers. PRM shows efficacy in the treatment of sleep disorders in mood disorders, schizophrenia, and neurocognitive disorders, but requires further confirmation. The additional use of PRM is supported for the withdrawal of chronic benzodiazepine therapies. The tolerability and safety of PRM are excellent, with ample evidence supporting the absence of tolerance and dependence.
CONCLUSIONS: Overall, PRM in circadian medicine is an effective chronopharmaceutical for restoring the sleep-wake rhythm in patients with insomnia disorder. This efficacy may also extend to sleep disorders associated with mood, neurodevelopmental and neurocognitive disorders, suggesting a further potential role in insomnia associated with various organic diseases.
A compound comprising a dimer of a dehydrosalicortin or a derivative, homologue, stereoisomer, prodrug or pharmaceutical salt thereof, wherein the dimer may be the product of a Diels-Alder reaction. The compound may be of the form R1-L-R2, wherein R1 and R2 are each independently selected from Formula III and L may be a tricyclodecadiene, particularly of Formula IIA or IIB: Wherein R3-6 are each independently selected from H or acetyl and R12-15 are each independently selected from H or OH. The compounds are disclosed to be of use in therapy, particularly cancer, compositions for such use are also disclosed. The cancer may be neuroblastoma, breast cancer, oesophageal cancer or ovarian cancer. The compounds may be obtained via extraction from a plant of the genus Salix, particularly the stem material thereof. The Salix family plant may be Salix miyabeana or a hybrid thereof.
Patients receive busulfan IV or oral every 6 hours on days -7 to -4 and etoposide IV on day -3. Patients then undergo autologous stem cell transplant on day 0.
INTRODUCTION: Polymorphous low grade neuroepithelial tumor of the young (PLNTY) is a newly described epileptogenic tumor first reported by Jason. T. Huse et al. in 2016. Only a very few cases have been reported so far and has been recently incorporated in the World Health Organization (WHO) Central Nervous System Classification of tumours, 5th edition, 2021. Here we report a rare case of PLNTY which closely resembles DNET (Dysembryoplastic neuroepithelial tumor) with plenty of interesting findings which would otherwise go unnoticed resulting in a nonspecific or misclassified diagnosis.
CASE REPORT: A 12 year old boy presented to the Neurosurgery OPD with seizures for the past five years and was given multiple antiepileptics for the same. Magnetic resonance imaging (MRI) showed a well-defined lobulated cortical mass with T1 hypo intensity and T2 hyperintensity in the left temporal lobe measuring 2.1 × 2 × 1.3 cm suggesting a DNET. Left temporal craniotomy and excision of the lesion was done. Frozen section showed features of a low grade glial neoplasm. Routine sections demonstrated polymorphous findings including oligodendroglia like features, neuronal nuclear pleomorphism, spindled astroglial elements, perivascular rosettes, calcification, and vascular mineralization. By immunohistochemistry (IHC), the tumor cells were diffusely positive for GFAP and CD34.Ki67 labelling index was low. A final diagnosis of PLNTY was made based on the above findings. The child has been epilepsy free since the past one-month post-surgery and is on follow up.
DISCUSSION/CONCLUSION: PLNTY is a newly discovered distinct pediatric low grade glial neoplasm which was earlier grouped into nonspecific forms of DNET. It is characterized morphologically and molecularly by the presence of oligodendroglial component, CD34 expression, BRAFV600E mutation and alterations in the MAP kinase pathway. They are known to behave in a low-grade fashion amenable to control by excision with occasional cases of recurrence reported. It is important to recognize and report similar tumors to determine the long-term risk of recurrence and create a more complete understanding on their radiology and molecular genetics.
A total of 47 consecutive patients with radiologic or histologic evidence of non metastatic liver cancer will be enrolled over a 2-4 year period. Subjects will receive oral Baclofen at the manufacturer's suggested maximal dose. Clinical, hematologic, biochemical, and radiologic features of liver function, tumor metastasis and recurrence will be monitored at regular time intervals over a 2 year treatment period. The primary study end point will be the event of interest (time to metastasis or recurrence). Secondary end points will include time to metastasis following recurrence, objective tumor responses (complete, partial and non response), response duration, survival and safety. It is hoped the results of this study will permit liver cancer patients to remain candidates for surgical resection and transplantation longer than would otherwise have been the case.
This invention discloses a gene for coding alpha--whelk toxin peptide (Vcl. 1) and its using method. And this invention belongs to the biology field. Vcl. 1 is the 16 peptide with two pairs of disulfide. And the method includes the following steps: recomposing the Vc1 into the expression carrier, transferring the host' cell, then cloning and expressing fused protein in the expression carrier, through hydrophilic chromatography, compositing and purifying, obtaining the Vc1. 1 peptide that has the antagonistic neuronal nicotine acetylcholine receptor activity. The quality is stable and the pure of the product is high, and the Vc1. d prepared in this invention has an important effect in the receptor researching and drug exploitation.
The present invention relates to a Chinese traditional patent medicine for treating condylomata acuminate, which takes more than 10 Chinese herbal medicines of honeysuckle flower, nutgrass galingale rhizome, sevenlobed yam rhizome, glabrous greenbrier rhizome etc. as the raw materials. The present invention has the effects of clearing heat-toxin, eliminating dampness and cooling blood. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the Chinese traditional patent medicine for treating condylomata acuminate. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
An aspect includes storing data elements in a storage space of a memory device. The storage space is allocated for an account of a subscriber of a universal subscriber identification system. An aspect also includes assigning subscriber-inputted security levels to the data elements. The security levels define varying degrees of access protections associated with the data elements. An aspect further includes generating a security envelope that includes a data element selected from the storage space. The security envelope is configured with an access protection scheme that is commensurate with a corresponding assigned security level. An aspect also includes providing access to the selected data element by another subscriber of the universal subscriber identification system via the security envelope. The access is provided in accordance with the access protection scheme.
The following actions have been demonstrated for endogenous human IGF-1:

Tissue Growth – 1) Skeletal growth occurs at the cartilage growth plates of the epiphyses of bones where stem cells divide to produce new cartilage cells or chondrocytes. The growth of chondrocytes is under the control of IGF-1 and GH. The chondrocytes become calcified so that new bone is formed allowing the length of the bones to increase. This results in skeletal growth until the cartilage growth plates fuse at the end of puberty. 2) Cell growth: IGF-1 receptors are present on most types of cells and tissues. IGF-1 has mitogenic activities that lead to an increased number of cells in the body. 3) Organ growth: Treatment of IGF-1 deficient rats with rhIGF-1 results in whole body and organ growth.

Carbohydrate Metabolism –IGF-1 suppresses hepatic glucose production and stimulates peripheral glucose utilization and therefore has a hypoglycemic potential. IGF-1 has inhibitory effects on insulin secretion.
Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. Follow up visits at 2 weeks, 3 and 6 months post intervention to collect clinical and patient-reported outcomes.
BACKGROUND: The growing demand for electrophysiology (EP) treatment in China presents a challenge for current EP care delivery systems. This study constructed a discrete event simulation (DES) model of an inpatient EP care delivery process, simulating a generalized inpatient journey of EP patients from admission to discharge in the cardiology department of a tertiary hospital in China. The model shows how many more patients the system can serve under different resource constraints by optimizing various phases of the care delivery process.
METHODS: Model inputs were based on and validated using real-world data, simulating the scheduling of limited resources among competing demands from different patient types. The patient stay consists of three stages, namely: the pre-operative stay, the EP procedure, and the post-operative stay. The model outcome was the total number of discharges during the simulation period. The scenario analysis presented in this paper covers two capacity-limiting scenarios (CLS): (1) fully occupied ward beds and (2) fully occupied electrophysiology laboratories (EP labs). Within each CLS, we investigated potential throughput when the length of stay or operative time was reduced by 10%, 20%, and 30%. The reductions were applied to patients with atrial fibrillation, the most common indication accounting for almost 30% of patients.
RESULTS: Model validation showed simulation results approximated actual data (137.2 discharges calculated vs. 137 observed). With fully occupied wards, reducing pre- and/or post-operative stay time resulted in a 1-7% increased throughput. With fully occupied EP labs, reduced operative time increased throughput by 3-12%.
CONCLUSIONS: Model validation and scenario analyses demonstrated that the DES model reliably reflects the EP care delivery process. Simulations identified which phases of the process should be optimized under different resource constraints, and the expected increases in patients served.
A composition comprising an aqueous preparation on the basis of keratin softening, which contains as a hair swelling and penetration agent, a quaternized amino lactam having formula (I), wherein m is an integer having a value of from 1 to 4; R is alkylene having from 3 to 8 carbon atoms and is optionally substituted with C1? to C4? alkyl; R1?, R2? and R3? are each independently selected from the group of alkyl, alkyl oxide, alkylhydroxy, alkoxy, aryl, aralkyl, alkaryl, and alkyl amidoalkyl radicals, said groups each having from 1 to 30 carbon atoms and at least one of R1?, R2? and R3? is a radical having from 8 to 30 carbon atoms; and X?- is a chloride, bromide or iodide anion. The invention also relates to the use of said quaternized compounds in hair structure altering compositions.
Approximately 13% of glatiramer acetate injection 20 mg per mL patients in the five placebo-controlled studies compared to 6% of placebo patients, and approximately 2% of patients exposed to glatiramer acetate injection 40 mg per mL in a placebo-controlled trial compared to 1% of placebo patients, experienced at least one episode of transient chest pain. While some of these episodes occurred in the context of the Immediate Post-Injection Reaction described above, many did not. The temporal relationship of this chest pain to an injection was not always known. The pain was usually transient, often unassociated with other symptoms, and appeared to have no clinical sequelae. Some patients experienced more than one such episode, and episodes usually began at least 1 month after the initiation of treatment. The pathogenesis of this symptom is unknown.